Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes

Luca Liberale, Fabrizio Montecucco, Ilaria Casetta, Silva Seraceni, Alessandro Trentini, Marina Padroni, Franco Dallegri, François Mach, Enrico Fainardi, Federico Carbone

Research output: Contribution to journalArticle

Abstract

Background: Soluble mediators have been investigated to predict the prognosis of acute ischaemic stroke (AIS). Among them, proprotein convertase subtilisin/kexin type 9 (PCSK9) might have both clinical and pathophysiological relevance. Materials and methods: All available serum samples from a cohort of patients with first AIS (n = 72) were tested for PCSK9 and included in this substudy analysis. The primary endpoint investigated the predictive value of early PCSK9 level variations (ΔPCSK9) from AIS onset to day 7 or from day 1 to day 7, towards a 90-day outcome by modified Rankin Scale (mRS). The secondary endpoint explored the association between ΔPCSK9 and the risk of major adverse cardiovascular events (MACEs). Results: Decreased serum PCSK9 levels at days 1 and 7 were associated with poor clinical outcomes at day 90. At the cut-off point identified by ROC curve analysis (−61·28 ng/mL), ΔPCSK9 day 7–day 1 predicted a poor mRS at day 90 after AIS. ΔPCSK9 day 7–day 1 ≤ −61·28 ng/mL was associated with an increased rate of MACEs. Conclusion: A decrease in PCSK9 levels was a predictor for poor outcome and increased MACEs after AIS. Additional studies targeting post-AIS PCSK9 levels and activity are required to clarify the prognostic and pathophysiological relevance of PCSK9 after AIS.

Original languageEnglish
Pages (from-to)1053-1062
Number of pages10
JournalEuropean Journal of Clinical Investigation
Volume46
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Proprotein Convertases
Subtilisin
Stroke
Serum
ROC Curve
Proprotein Convertase 9

Keywords

  • Cholesterol
  • injury
  • ischaemic stroke
  • PCSK9

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Clinical Biochemistry

Cite this

Liberale, L., Montecucco, F., Casetta, I., Seraceni, S., Trentini, A., Padroni, M., ... Carbone, F. (2016). Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes. European Journal of Clinical Investigation, 46(12), 1053-1062. https://doi.org/10.1111/eci.12692

Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes. / Liberale, Luca; Montecucco, Fabrizio; Casetta, Ilaria; Seraceni, Silva; Trentini, Alessandro; Padroni, Marina; Dallegri, Franco; Mach, François; Fainardi, Enrico; Carbone, Federico.

In: European Journal of Clinical Investigation, Vol. 46, No. 12, 01.12.2016, p. 1053-1062.

Research output: Contribution to journalArticle

Liberale, L, Montecucco, F, Casetta, I, Seraceni, S, Trentini, A, Padroni, M, Dallegri, F, Mach, F, Fainardi, E & Carbone, F 2016, 'Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes', European Journal of Clinical Investigation, vol. 46, no. 12, pp. 1053-1062. https://doi.org/10.1111/eci.12692
Liberale L, Montecucco F, Casetta I, Seraceni S, Trentini A, Padroni M et al. Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes. European Journal of Clinical Investigation. 2016 Dec 1;46(12):1053-1062. https://doi.org/10.1111/eci.12692
Liberale, Luca ; Montecucco, Fabrizio ; Casetta, Ilaria ; Seraceni, Silva ; Trentini, Alessandro ; Padroni, Marina ; Dallegri, Franco ; Mach, François ; Fainardi, Enrico ; Carbone, Federico. / Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes. In: European Journal of Clinical Investigation. 2016 ; Vol. 46, No. 12. pp. 1053-1062.
@article{c1d6c48e8198408084124de8d6342cb7,
title = "Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes",
abstract = "Background: Soluble mediators have been investigated to predict the prognosis of acute ischaemic stroke (AIS). Among them, proprotein convertase subtilisin/kexin type 9 (PCSK9) might have both clinical and pathophysiological relevance. Materials and methods: All available serum samples from a cohort of patients with first AIS (n = 72) were tested for PCSK9 and included in this substudy analysis. The primary endpoint investigated the predictive value of early PCSK9 level variations (ΔPCSK9) from AIS onset to day 7 or from day 1 to day 7, towards a 90-day outcome by modified Rankin Scale (mRS). The secondary endpoint explored the association between ΔPCSK9 and the risk of major adverse cardiovascular events (MACEs). Results: Decreased serum PCSK9 levels at days 1 and 7 were associated with poor clinical outcomes at day 90. At the cut-off point identified by ROC curve analysis (−61·28 ng/mL), ΔPCSK9 day 7–day 1 predicted a poor mRS at day 90 after AIS. ΔPCSK9 day 7–day 1 ≤ −61·28 ng/mL was associated with an increased rate of MACEs. Conclusion: A decrease in PCSK9 levels was a predictor for poor outcome and increased MACEs after AIS. Additional studies targeting post-AIS PCSK9 levels and activity are required to clarify the prognostic and pathophysiological relevance of PCSK9 after AIS.",
keywords = "Cholesterol, injury, ischaemic stroke, PCSK9",
author = "Luca Liberale and Fabrizio Montecucco and Ilaria Casetta and Silva Seraceni and Alessandro Trentini and Marina Padroni and Franco Dallegri and Fran{\cc}ois Mach and Enrico Fainardi and Federico Carbone",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/eci.12692",
language = "English",
volume = "46",
pages = "1053--1062",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Blackwell Publishing Ltd",
number = "12",

}

TY - JOUR

T1 - Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes

AU - Liberale, Luca

AU - Montecucco, Fabrizio

AU - Casetta, Ilaria

AU - Seraceni, Silva

AU - Trentini, Alessandro

AU - Padroni, Marina

AU - Dallegri, Franco

AU - Mach, François

AU - Fainardi, Enrico

AU - Carbone, Federico

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Soluble mediators have been investigated to predict the prognosis of acute ischaemic stroke (AIS). Among them, proprotein convertase subtilisin/kexin type 9 (PCSK9) might have both clinical and pathophysiological relevance. Materials and methods: All available serum samples from a cohort of patients with first AIS (n = 72) were tested for PCSK9 and included in this substudy analysis. The primary endpoint investigated the predictive value of early PCSK9 level variations (ΔPCSK9) from AIS onset to day 7 or from day 1 to day 7, towards a 90-day outcome by modified Rankin Scale (mRS). The secondary endpoint explored the association between ΔPCSK9 and the risk of major adverse cardiovascular events (MACEs). Results: Decreased serum PCSK9 levels at days 1 and 7 were associated with poor clinical outcomes at day 90. At the cut-off point identified by ROC curve analysis (−61·28 ng/mL), ΔPCSK9 day 7–day 1 predicted a poor mRS at day 90 after AIS. ΔPCSK9 day 7–day 1 ≤ −61·28 ng/mL was associated with an increased rate of MACEs. Conclusion: A decrease in PCSK9 levels was a predictor for poor outcome and increased MACEs after AIS. Additional studies targeting post-AIS PCSK9 levels and activity are required to clarify the prognostic and pathophysiological relevance of PCSK9 after AIS.

AB - Background: Soluble mediators have been investigated to predict the prognosis of acute ischaemic stroke (AIS). Among them, proprotein convertase subtilisin/kexin type 9 (PCSK9) might have both clinical and pathophysiological relevance. Materials and methods: All available serum samples from a cohort of patients with first AIS (n = 72) were tested for PCSK9 and included in this substudy analysis. The primary endpoint investigated the predictive value of early PCSK9 level variations (ΔPCSK9) from AIS onset to day 7 or from day 1 to day 7, towards a 90-day outcome by modified Rankin Scale (mRS). The secondary endpoint explored the association between ΔPCSK9 and the risk of major adverse cardiovascular events (MACEs). Results: Decreased serum PCSK9 levels at days 1 and 7 were associated with poor clinical outcomes at day 90. At the cut-off point identified by ROC curve analysis (−61·28 ng/mL), ΔPCSK9 day 7–day 1 predicted a poor mRS at day 90 after AIS. ΔPCSK9 day 7–day 1 ≤ −61·28 ng/mL was associated with an increased rate of MACEs. Conclusion: A decrease in PCSK9 levels was a predictor for poor outcome and increased MACEs after AIS. Additional studies targeting post-AIS PCSK9 levels and activity are required to clarify the prognostic and pathophysiological relevance of PCSK9 after AIS.

KW - Cholesterol

KW - injury

KW - ischaemic stroke

KW - PCSK9

UR - http://www.scopus.com/inward/record.url?scp=84995976611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995976611&partnerID=8YFLogxK

U2 - 10.1111/eci.12692

DO - 10.1111/eci.12692

M3 - Article

AN - SCOPUS:84995976611

VL - 46

SP - 1053

EP - 1062

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 12

ER -